At the same time, high expression of CKS2 in various cancers such as liver cancer (37), breast cancer (58) and prostate cancer (26) is associated with malignant phenotypes in cancer progression, such as promoting proliferation, migration and invasion, while inhibition of CKS2 can reverse these pathological processes. Here, CKS2 is linked to prostate carcinoma.